53,980 Shares in Pharvaris (NASDAQ:PHVS) Purchased by State Street Corp

State Street Corp acquired a new stake in Pharvaris (NASDAQ:PHVS) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 53,980 shares of the company’s stock, valued at approximately $1,000,000.

A number of other institutional investors have also bought and sold shares of the business. HighVista Strategies LLC grew its position in shares of Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock valued at $422,000 after purchasing an additional 6,018 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pharvaris during the third quarter worth $906,000. Patient Square Capital LP purchased a new stake in Pharvaris in the 3rd quarter valued at $4,488,000. Sofinnova Investments Inc. increased its stake in shares of Pharvaris by 2.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock worth $11,309,000 after acquiring an additional 16,862 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C raised its holdings in shares of Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after acquiring an additional 335,687 shares during the period.

Analyst Upgrades and Downgrades

Separately, Oppenheimer upped their price objective on shares of Pharvaris from $38.00 to $42.00 and gave the company an “outperform” rating in a report on Friday, September 6th.

Pharvaris Stock Down 3.3 %

Shares of PHVS opened at $18.54 on Friday. Pharvaris has a fifty-two week low of $15.37 and a fifty-two week high of $33.00. The company has a market cap of $590.31 million, a P/E ratio of -6.62 and a beta of -3.17. The firm’s 50 day moving average price is $20.82 and its 200 day moving average price is $19.37.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.